Antibody-Drug Conjugates

(Image: Getty/BrianAJackson)

AZ’s ADC receives priority review

By Ben Hargreaves

US FDA provides AZ and Daiichi Sankyo’s ADC for the treatment of metastatic breast cancer priority review, with a decision set for Q2 2020.

Follow us

Products

View more

Webinars